Opioid Withdrawal Syndrome Market Size (7MM) was ~USD 1,302 Million in 2022 and It is projected to grow by 2034, estimates DelveInsight

DelveInsight's "Opioid Withdrawal Syndrome Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Opioid Withdrawal Syndrome, historical and forecasted epidemiology and the Opioid Withdrawal Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock key insights into the Opioid Withdrawal Syndrome Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Opioid Withdrawal Syndrome Market Size- https://www.delveinsight.com/sample-request/opioid-withdrawal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Opioid Withdrawal Syndrome Market Report
• According to DelveInsight estimations, 9,077,124 Number of cases with long-term opioid usage were found in 2022 in the 7MM.
• As per DelveInsight's estimations, the total number of cases with opioid withdrawal syndrome in the United States were approximately 7,087,561 in 2022 and are projected to decrease during the forecast period.
• According to DelveInsight's estimates, the number of opioid misuse cases in EU4 and the UK were found to be approximately 1,365,293 in 2022.
• The leading Opioid withdrawal Syndrome Companies such as DemeRx IB, Inc., atai Life Sciences, MediciNova, BioXcel Therapeutics Inc., and others.
• Promising Opioid withdrawal Syndrome Therapies such as Dexmedetomidine, Lofexidine, DMX-1002, BXCL501 (180 micrograms), Oxycodone, and others.

Stay ahead in the competitive landscape of the Opioid Withdrawal Syndrome Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Opioid Withdrawal Syndrome Treatment Market Size- https://www.delveinsight.com/sample-request/opioid-withdrawal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Opioid Withdrawal Syndrome Epidemiology Segmentation in the 7MM
• Number of Opioid misuse cases
• Number of cases with long-term opioid usage
• Total Opioid Withdrawal Syndrome Cases

Download the report to understand which factors are driving Opioid Withdrawal Syndrome epidemiology trends @ Opioid Withdrawal Syndrome Prevalence- https://www.delveinsight.com/sample-request/opioid-withdrawal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Opioid Withdrawal Syndrome Marketed Drugs
• LUCEMYRA (lofexidine hydrochloride): US World Meds LLC
LUCEMYRA is an oral, selective alpha 2-adrenergic receptor agonist that reduces the release of norepinephrine. LUCEMYRA is not an opioid drug. While LUCEMYRA may lessen the severity of withdrawal symptoms, it may not completely prevent them and is only approved for treatment for up to 14 days. LUCEMYRA is not a treatment for OUD but can be used as part of a broader, long-term treatment plan for managing OUD. LUCEMYRA is under license from Britannia Pharmaceuticals, Ltd. USWM, LLC is the exclusive licensee and distributor of LUCEMYRA in the United States and Its territories.

Opioid Withdrawal Syndrome Emerging Drugs
• DMX-1002 (Ibogaine HCl): DemeRx IB, Inc. /atai Life Sciences
DMX-1002 is an oral formulation of ibogaine, an oneirogenic indole alkaloid with cholinergic, glutamatergic, and monoaminergic receptor modulatory activity. Ibogaine is a natural indole alkaloid derived from the West African iboga plant and has previously been marketed as a stimulant and antidepressant in France under the brand name Lambarène. Known for its oneirophrenic and hallucinogenic properties, uncontrolled data from hundreds of patients suggest that Ibogaine is effective as both an acute detoxifier and treatment for opioid addiction. At present, DMX-1002 is in Phase I/II of clinical development for the treatment of Opioid Withdrawal Syndrome. As per the DemeRx pipeline, the drug is being developed for opioid withdrawal management and relapse prevention, whereas as per atai Life Sciences pipeline, the drug is being developed for OUD treatment.

• MN-166: Medicinova
MN-166 is a first in class, orally bioavailable, small molecule glial attenuator that suppresses pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6 and may upregulate the anti-inflammatory cytokine IL-10. It has additionally been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. While considered a New Molecular Entity, or NME, in the United States and Europe, it involves redirection of an approved drug, ibudilast, which was first approved in Japan more than 20 years ago.

Discover the future of Opioid Withdrawal Syndrome treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Opioid Withdrawal Syndrome Market Drivers and Barriers- https://www.delveinsight.com/sample-request/opioid-withdrawal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Opioid Withdrawal Syndrome Market Outlook
The treatment approach for Opioid Withdrawal Syndrome depends on the severity of the symptoms experienced by the individual. In cases of mild withdrawal, patients are encouraged to prioritize hydration by consuming at least 2-3 L of water daily and may benefit from supplementation with vitamins B and C to support overall health. Typically, symptomatic treatment and supportive care suffice for managing mild symptoms, focusing on alleviating discomfort and ensuring the patient's well-being during this phase.

Scope of the Opioid Withdrawal Syndrome Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Opioid withdrawal Syndrome Companies- DemeRx IB, Inc., atai Life Sciences, MediciNova, BioXcel Therapeutics Inc., and others.
• Opioid withdrawal Syndrome Therapies- Dexmedetomidine, Lofexidine, DMX-1002, BXCL501 (180 micrograms), Oxycodone, and others.

Explore the dynamics of the Opioid Withdrawal Syndrome Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Opioid Withdrawal Syndrome Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/opioid-withdrawal-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Opioid Withdrawal Syndrome Market Overview at a Glance
4. Opioid Withdrawal Syndrome Epidemiology and Market Methodology
5. Executive Summary
6. Key Events
7. Opioid Withdrawal Syndrome: Disease Background and Overview
8. Opioid Withdrawal Syndrome Epidemiology and Patient Population
9. Patient Journey
10. Opioid Withdrawal Syndrome Marketed Drugs
11. Opioid Withdrawal Syndrome Emerging Drugs
12. Opioid Withdrawal Syndrome: Market Analysis
13. Key Opinion Leaders' Views
14. Opioid Withdrawal Syndrome SWOT Analysis
15. Opioid Withdrawal Syndrome Unmet Needs
16. Opioid Withdrawal Syndrome Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.